AC Immune SA (ACIU)

2,3900 -0,0500 (-2,05%) Alla chiusura: 04:00PM EDT

AC Immune SA

Building B
EPFL Innovation Park
Lausanne 1015
Switzerland
41 21 345 91 21
https://www.acimmune.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 133

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Andrea Pfeifer Ph.D.	Co-Founder, CEO & Director	1,09M	N/D	1957
Mr. Christopher Roberts	CFO & VP of Finance	N/D	N/D	1990
Mr. Piergiorgio Donati	Chief Technical Operations Officer	N/D	N/D	1971
Mr. Jean-Fabien Monin	Chief Administrative Officer	N/D	N/D	1971
Mr. Howard Donovan	Chief HR Officer	N/D	N/D	1976
Ms. Madiha Derouazi	Chief Scientific Officer	N/D	N/D	1973
Dr. Gary Anthony Waanders Ph.D.	Senior VP of Investor Relations & Corporate Communications	N/D	N/D	1964
Mr. Alexandre Caratsch	General Counsel	N/D	N/D	1966
Mr. Julian Snow	VP of U.S. Finance & Corporate Development	N/D	N/D	N/D
Dr. David T. Hickman	Head of AD - SME	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Governance aziendale

L'ISS Governance QualityScore di AC Immune SA al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.